Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.
about
Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnosticsProspects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderlyStrategies for modern biomarker and drug development in oncology.The Use of Non-Variant Sites to Improve the Clinical Assessment of Whole-Genome Sequence Data.Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.A framework for genomic biomarker actionability and its use in clinical decision makingIncidence of kiaa1549-braf fusion gene in Egyptian pediatric low grade glioma.Oncogenic HER2 fusions in gastric cancer.Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.BRAF Fusion Analysis in Pilocytic Astrocytomas: KIAA1549-BRAF 15-9 Fusions Are More Frequent in the Midline Than Within the CerebellumPersonalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicineSystemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.Molecular diagnostics in soft tissue sarcomas and gastrointestinal stromal tumors.Melanoma BRAF fusions--letter.Melanoma BRAF fusions--response.Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.Debunking the Delusion That Precision Oncology Is an Illusion.Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma.Natural (and Unnatural) Small Molecules as Pharmacological Chaperones and Inhibitors in Cancer.Recurrent BRAF Gene Rearrangements in Myxoinflammatory Fibroblastic Sarcomas, but Not Hemosiderotic Fibrolipomatous Tumors.Exceptional responders: in search of the science behind the miracle cancer cures.The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope.Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors.Comprehensive genomic profiling of malignant phyllodes tumors of the breast.Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway
P2860
Q26864332-F997CD7B-61ED-4243-A0A9-EC6454A8D1A3Q27025344-5DD758E5-7F09-4785-9F1C-B339DC9648FEQ30590270-3B9F5FE2-CC61-40CD-A2DE-C05E48DFFB6AQ30978835-4C322B58-EF00-4B06-BA14-AEBB6B9A5BBCQ33889152-FE2D3819-85DF-4CF5-8A4B-7FC8C632FAF7Q34781122-3E1F1D6D-2C21-4D85-97FA-64A2CE1FC64BQ35348996-EBE15581-DAC9-41B9-AFA0-BA7C576E47AFQ35414389-AB47413C-AF92-4B66-B014-850EC553EB46Q35963400-4288113D-150C-4AE9-816F-CFF206AFB516Q36009738-EFB64B99-E7DE-4BE4-AE0B-7F7EDDE39C2FQ36562114-A19831E1-D8B3-4D45-B1ED-B3CFC83FED2BQ37204286-0E375B0C-868A-4FA7-BBB5-F65AC770582FQ37308973-3A8F800B-EA24-4319-BF83-E989500A26B1Q37342909-0B30A1EE-5E12-4F41-8971-7D03492A2451Q38378763-A0BE8C7F-EA79-40F0-BA27-A87DFACEF2FDQ43070386-6479BC77-6F69-4332-ABA4-314E18030CA9Q43204404-82C39730-C64D-4830-AA95-08AD475C80F7Q44727423-201B1FE4-D09A-41A9-B1FD-8476E0220E02Q46539715-4946FFB9-708B-4B70-AEB6-4A64EE1B2B90Q47649693-5D015478-2EED-4986-9B10-647706CA8236Q47673940-E8D53C42-600F-42A3-A0A3-618FA0A913D0Q47704002-A896E01F-65F3-4C4E-BA97-EC9AB7CF55B8Q48639229-F6F908C1-1F0F-4ADC-9D35-D34215A214B5Q50067454-3140F139-8696-4A17-98A5-3A58C244579CQ52759227-C9FCDCA1-B496-44BC-84EA-9F8367F583A6Q52905583-FDF814B6-82BC-43AC-B89B-325B52B7CBF5Q58804958-D839D387-1B14-4A00-BD94-1DB096920A48
P2860
Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeted therapy by combined i ...... KIAA1549-BRAF fusion protein.
@en
Targeted therapy by combined i ...... KIAA1549-BRAF fusion protein.
@nl
type
label
Targeted therapy by combined i ...... KIAA1549-BRAF fusion protein.
@en
Targeted therapy by combined i ...... KIAA1549-BRAF fusion protein.
@nl
prefLabel
Targeted therapy by combined i ...... KIAA1549-BRAF fusion protein.
@en
Targeted therapy by combined i ...... KIAA1549-BRAF fusion protein.
@nl
P2093
P2860
P356
P1476
Targeted therapy by combined i ...... KIAA1549-BRAF fusion protein.
@en
P2093
Dejka Araujo
Gary A Palmer
Jeffrey S Ross
Phillip J Stephens
Shannon N Westin
Siraj M Ali
Vincent A Miller
Vivek Subbiah
Wei-Lien Wang
P2860
P2888
P356
10.1186/1756-8722-7-8
P577
2014-01-14T00:00:00Z
P5875
P6179
1053512252